Oregon BioEvolution: Now available...
We extend a special thank you to the many companies and organizations that are helping to promote
Oregon's biotechnology, medical device and healthcare industry, including Amgen, Economic Development
For Central Oregon, Davis Wright Tremaine, Fred Hutchinson Cancer Research Center, Lease Crutcher Lewis, Merck & Co.,
Oregon Bioscience Association, Oregon Health & Science University, Perkins Coie, Portland Development Commission,
Ratner BioMedical, SAB Architects, Tonkon Torp, ZymoGenetics and others -- sponsors of the
first ever Oregon BioEvolution poster.
Oregon BioEvolution is a one-of-a-kind genealogy chart that illustrates the founding "technology origins" of more
than 100 biotechnology and medical device firms located in the state of Oregon.
More...
|
|
2008 "Sail into Summer" - WBBA Summer Social

You’re invited to the WBBA’s Summer Social, better known as the “bioscience bash of the year.” This year’s
opportunity to meet and chat with your fellow WBBA members will be at the Naval Reserve Center at South Lake Union Park
on July 17 from 4:30-7:30 p.m. “Sail Into Summer” will feature live music, appetizers, beverages and a number of wild
and crazy sponsor displays. To sponsor, follow the link below or
email pamlove@washbio.org.
Register Today!
Sponsor information
|
Local News...
Free News Release Posting & Archiving Service
- Insecticide Movento(R) approved in United States and Canada The new insecticidal active ingredient spirotetramat from Bayer CropScience has been granted regulatory approval in the strategically important markets in the United States and Canada. Spirotetramat will be marketed worldwide under the brand name Movento(R).
Bayer July 03, 2008
- Wyeth and Progenics receive approval from European Commission for RELISTOR Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals announced that the companies have received marketing approval for RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection from the European Commission.
Progenics Pharmaceuticals, Inc. July 03, 2008
- Orelle concludes phase ll clinical trials Orelle Corportion (Seattle) announces the conclusion of Phase ll Clinical Trials for its Pelvic Floor Muscle Exercise Device and related Exercise Program for the Relief and Prevention of Urinary Stress Leakage in Women at the Auckland University of Technology in New Zealand.
Orelle Corporation Ltd. July 03, 2008
- Orelle awarded Price Waterhouse Investor Choice Award Orelle Corporation (Seattle), developer of a Pelvic Floor Muscle Exercise Device for the Relief and Prevention of Urinary Stress Leakage in Women was awarded the Price Waterhouse 'Investor Choice Award for the Best Pre-Revenue Company' at the recent Vancouver, BC Angel Investment Forum.
Orelle Corporation Ltd July 03, 2008
- Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen's hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in 3Q 2008.
Bayer July 02, 2008
More... | Submit News Release | National News
|